Engineering and pharmacology of blood-brain barrier-permeable bispecific antibodies

Advances in Pharmacology

Volumn 71, Issue , 2014, Pages 301-335

  Stanimirovic, Danica ^a   Kemmerich, Kristin ^a   Haqqani, Arsalan S ^a   Farrington, Graham K ^b  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b BIOGEN   (United States)

Author keywords

Bispecific antibodies; Blood brain barrier; Receptor mediated transcytosis; Single domain antibodies

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; BISPECIFIC ANTIBODY; GALANIN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1 ANTIBODY; LEUCINE ENKEPHALIN[2 DEXTRO ALANINE 6 ARGININE]; MONOCLONAL ANTIBODY; NANOBODY; RECEPTOR ANTIBODY; RITUXIMAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRANSFERRIN RECEPTOR; TRANSFERRIN RECEPTOR ANTIBODY; TRASTUZUMAB; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIBODY ENGINEERING; ANTIBODY LIBRARY; ANTIBODY SCREENING; ANTIGEN BINDING; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; CENTRAL NERVOUS SYSTEM; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG TARGETING; HUMAN; IMMUNOTHERAPY; INFLAMMATORY PAIN; MACROMOLECULE; MEMBRANE PERMEABILITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PROCESS OPTIMIZATION; TRANSCYTOSIS; ANIMAL; BIOLOGICAL MODEL; DRUG DESIGN; METABOLISM; PERMEABILITY;

ANIMALS; ANTIBODIES, BISPECIFIC; BLOOD-BRAIN BARRIER; DRUG DESIGN; HUMANS; MODELS, BIOLOGICAL; PERMEABILITY;

EID: 84907982724     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/bs.apha.2014.06.005     Document Type: Chapter

References (118)

1. Abbott N.J. Evidence for bulk flow of brain interstitial fluid: Significance for physiology and pathology. Neurochemistry International 2004, 45:545-552.
2. Abbott N.J., Patabendige A.A.K., Dolman D.E.M., Yusof S.R., Begley D.J. Structure and function of the blood-brain barrier. Neurobiology of Disease 2010, 37:13-25.
3. Abulrob A., Sprong H., Van Bergen en Henegouwen P., Stanimirovic D. The blood-brain barrier transmigrating single domain antibody: Mechanisms of transport and antigenic epitopes in human brain endothelial cells. Journal of Neurochemistry 2005, 95:1201-1214.
4. Abuqayyas L., Balthasar J.P. Investigation of the role of FcγR and FcRn in mAb distribution to the brain. Molecular Pharmaceutics 2013, 10:1505-1513.
5. Aigner M., Feulner J., Schaffer S., Kischel R., Kufer P., Schneider K., et al. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia 2013, 27:1107-1115.
6. Alata W., Paris-Robidas S., Emond V., Bourasset F., Calon F. Brain uptake of a fluorescent vector targeting the transferrin receptor: A novel application of in situ brain perfusion. Molecular Pharmaceutics 2014, 11:243-253.
7. Anderson G.J., Powell L.W., Halliday J.W. Transferrin receptor distribution and regulation in the rat small intestine. Effect of iron stores and erythropoiesis. Gastroenterology 1990, 98:576-585.
8. Atwal J.K., Chen Y., Chiu C., Mortensen D.L., Meilandt W.J., Liu Y., et al. A therapeutic antibody targeting BACE1 inhibits amyloid-Β production in vivo. Science Translational Medicine 2011, 3. 84ra43.
9. Badhwar A., Stanimirovic D.B., Hamel E., Haqqani A.S. The proteome of mouse cerebral arteries. Journal of Cerebral Blood Flow & Metabolism 2014, 34:1033-1046.
10. Bell R.D., Ehlers M.D. Breaching the blood-brain barrier for drug delivery. Neuron 2014, 81:1-3.
11. Bien C.G., Vincent A., Barnett M.H., Becker A.J., Blümcke I., Graus F., et al. Immunopathology of autoantibody-associated encephalitides: Clues for pathogenesis. Brain 2012, 135:1622-1638.
12. Bien-Ly N., Yu Y.J., Bumbaca D., Elstrott J., Boswell C.A., Zhang Y., et al. Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. The Journal of Experimental Medicine 2014, 211:233-244.
13. Boado R., Hui E., Lu J., Pardridge W. IgG-enzyme fusion protein: Pharmacokinetics and anti-drug antibody response in rhesus monkeys. Bioconjugate Chemistry 2012, 1:97-104.
14. Braen A.P.J.M., Perron J., Tellier P., Catala A.R., Kolaitis G., Geng W. A 4-week intrathecal toxicity and pharmacokinetic study with Trastuzumab in cynomolgus monkeys. International Journal of Toxicology 2010, 29:259-267.
15. Brüggemann M., Caskey H.M., Teale C., Waldmann H., Williams G.T., Surani M.A., et al. A repertoire of monoclonal antibodies with human heavy chains from transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 1989, 86:6709-6713.
16. Calabria A.R., Shusta E.V. Blood-brain barrier genomics and proteomics: Elucidating phenotype, identifying disease targets and enabling brain drug delivery. Drug Discovery Today 2006, 11:792-799.
17. Calabria A.R., Shusta E.V. A genomic comparison of in vivo and in vitro brain microvascular endothelial cells. Journal of Cerebral Blood Flow & Metabolism 2008, 28:135-148.
18. Cao Y., Balthasar J.P., Jusko W.J. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. Journal of Pharmacokinetics and Pharmacodynamics 2013, 40:597-607.
19. Chames P., Baty D. Bispecific antibodies for cancer therapy: The light at the end of the tunnel?. MAbs 2009, 1:539-547.
20. Chen Y., Balthasar J.P. Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn. The AAPS Journal 2012, 14:850-859.
21. Cooper P.R., Ciambrone G.J., Kliwinski C.M., Maze E., Johnson L., Li Q., et al. Efflux of monoclonal antibodies from rat brain by neonatal Fc receptor, FcRn. Brain Research 2013, 1534:13-21.
22. Couch J.A., Yu Y.J., Zhang Y., Tarrant J.M., Fuji R.N., Meilandt W.J., et al. Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Science Translational Medicine 2013, 5:1-12. 183ra57.
23. Cserr H.F., Cooper D.N., Suri P.K., Patlak C.S. Efflux of radiolabeled polyethylene glycols and albumin from rat brain. The American Journal of Physiology 1981, 240:F319-F328.
24. Dalmau J., Lancaster E., Martinez-Hernandez E., Rosenfeld M.R., Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. The Lancet Neurology 2011, 10:63-74.
25. Darnell R.B., Posner J.B. Paraneoplastic syndromes involving the nervous system. The New England Journal of Medicine 2003, 349:1543-1554.
26. De Lange E.C.M., Danhof M. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: Implications of the barriers between blood and brain. Clinical Pharmacokinetics 2002, 41:691-703.
27. Dehouck B., Fenart L., Dehouck M.P., Pierce A,., Torpier G., Cecchelli R. A new function for the LDL receptor: Transcytosis of LDL across the blood-brain barrier. The Journal of Cell Biology 1997, 138:877-889.
28. Deloire M.S.A., Touil T., Brochet B., Dousset V., Caillé J.-M., Petry K.G. Macrophage brain infiltration in experimental autoimmune encephalomyelitis is not completely compromised by suppressed T-cell invasion: In vivo magnetic resonance imaging illustration in effective anti-VLA-4 antibody treatment. Multiple Sclerosis 2004, 10:540-548.
29. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:8850-8855.
30. Demeule M., Currie J.-C., Bertrand Y., Ché C., Nguyen T., Régina A., et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. Journal of Neurochemistry 2008, 106:1534-1544.
31. Demeule M., Régina A., Ché C., Poirier J., Nguyen T., Gabathuler R., et al. Identification and design of peptides as a new drug delivery system for the brain. The Journal of Pharmacology and Experimental Therapeutics 2008, 324:1064-1072.
32. Enerson B.E., Drewes L.R. The rat blood-brain barrier transcriptome. Journal of Cerebral Blood Flow & Metabolism 2006, 26:959-973.
33. Farrington G.K., Caram-Salas N., Haqqani A.S., Brunette E., Eldredge J., Pepinsky R.B., et al. A novel platform for engineering blood-brain barrier crossing bispecific biologics. FASEB Journal 2014, in press.
34. Friden P.M., Walus L.R., Musso G.F., Taylor M.a, Malfroy B., Starzyk R.M. Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proceedings of the National Academy of Sciences of the United States of America 1991, 88:4771-4775.
35. Gabathuler R. Blood-brain barrier transport of drugs for the treatment of brain diseases. CNS & Neurological Disorders: Drug Targets 2009, 8:195-204.
36. Garberg P., Ball M., Borg N., Cecchelli R., Fenart L., Hurst R.D., et al. In vitro models for the blood-brain barrier. Toxicology in Vitro 2005, 19:299-334.
37. Ghosh A.K., Brindisi M., Tang J. Developing Β-secretase inhibitors for treatment of Alzheimer's disease. Journal of Neurochemistry 2012, 120(Suppl.):71-83.
38. Güssow D., Seemann G. Humanization of monoclonal antibodies. Methods in Enzymology 1991, 203:99-121.
39. Hamers-Casterman C., Atarhouch T., Muyldermans S., Robinson G., Hamers C., Songa E.B., et al. Naturally occurring antibodies devoid of light chains. Nature 1993, 363:446-448.
40. Haqqani A.S., Caram-Salas N., Ding W., Brunette E., Delaney C.E., Baumann E., et al. Multiplexed evaluation of serum and CSF pharmacokinetics of brain-targeting single-domain antibodies using a nanoLC-SRM-ILIS method. Molecular Pharmaceutics 2013, 10:1542-1556.
41. Haqqani A.S., Delaney C.E., Tremblay T.-L., Sodja C., Sandhu J.K., Stanimirovic D.B. Method for isolation and molecular characterization of extracellular microvesicles released from brain endothelial cells. Fluids and Barriers of the CNS 2013, 10:4.
42. Haqqani A.S., Hill J.J., Mullen J., Stanimirovic D.B. Methods to study glycoproteins at the blood-brain barrier using mass spectrometry. Methods in Molecular Biology 2011, 686:337-353.
43. Haqqani A.S., Kelly J.F., Stanimirovic D.B. Quantitative protein profiling by mass spectrometry using label-free proteomics. Methods in Molecular Biology 2008, 439:241-256.
44. Harris-White M.E., Frautschy S.A. Low density lipoprotein receptor-related proteins (LRPs), Alzheimer's and cognition. Current Drug Targets. CNS and Neurological Disorders 2005, 4:469-480.
45. Henderson S.J., Andersson C., Narwal R., Janson J., Goldschmidt T.J., Appelkvist P., et al. Sustained peripheral depletion of amyloid-Β with a novel form of neprilysin does not affect central levels of amyloid-Β. Brain 2014, 137:553-564.
46. Holliger P., Hudson P.J. Engineered antibody fragments and the rise of single domains. Nature Biotechnology 2005, 23:1126-1136.
47. Hughes E.G., Peng X., Gleichman A.J., Lai M., Zhou L., Tsou R., et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. The Journal of Neuroscience 2010, 30:5866-5875.
48. Hussack G., Keklikian A., Alsughayyir J., Hanifi-Moghaddam P., Arbabi-Ghahroudi M., van Faassen H., et al. A V(L) single-domain antibody library shows a high-propensity to yield non-aggregating binders. Protein Engineering, Design & Selection 2012, 25:313-318.
49. Iliff J.J., Wang M., Liao Y., Plogg B.A., Peng W., Gundersen G.A., et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid Β. Science Translational Medicine 2012, 4. 147ra111.
50. Iqbal U., Abulrob A., Stanimirovic D.B. Integrated platform for brain imaging and drug delivery across the blood-brain barrier. Methods in Molecular Biology 2011, 686:465-481.
51. Jain PharmaBiotech. (2010). Drug delivery in central nervous system disorders: Technologies, companies and markets.
52. Jefferies W.A., Brandon M.R., Hunt S.V., Williams A.F., Gatter K.C., Mason D.Y. Transferrin receptor on endothelium of brain capillaries. Nature 1984, 312:162-163.
53. Johanson C.E., Stopa E.G., McMillan P.N. The blood-cerebrospinal fluid barrier: Structure and functional significance. Methods in Molecular Biology 2011, 686:101-131.
54. Jolliffe L.K. Humanized antibodies: Enhancing therapeutic utility through antibody engineering. International Reviews of Immunology 1993, 10:241-250.
55. Jones P.T., Dear P.H., Foote J., Neuberger M.S., Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986, 321:522-525.
56. Jones A.R., Shusta E.V. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharmaceutical Research 2007, 24:1759-1771.
57. Jones A.R., Stutz C.C., Zhou Y., Marks J.D., Shusta E.V. Identifying blood-brain-barrier selective single-chain antibody fragments. Biotechnology Journal 2014, 9:664-674.
58. Kim D.Y., To R., Kandalaft H., Ding W., van Faassen H., Luo Y., et al. Antibody light chain variable domains and their biophysically improved versions for human immunotherapy. MAbs 2014, 6:219-235.
59. Kurzrock R., Gabrail N., Chandhasin C., Moulder S., Smith C., Brenner A., et al. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Molecular Cancer Therapeutics 2012, 11:308-316.
60. La Merie Publishing. (2013). Antibody technologies and attrition rates: An industry analysis.
61. Lauwereys M., Arbabi Ghahroudi M., Desmyter A., Kinne J., Hölzer W., De Genst E., et al. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. The EMBO Journal 1998, 17:3512-3520.
62. Lee E.-C., Liang Q., Ali H., Bayliss L., Beasley A., Bloomfield-Gerdes T., et al. Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery. Nature Biotechnology 2014, 32:356-363.
63. Levites Y., Smithson L.A., Price R.W., Dakin R.S., Yuan B., Sierks M.R., et al. Insights into the mechanisms of action of anti-abeta antibodies in Alzheimer's disease mouse models. FASEB Journal 2006, 20:2576-2578.
64. Lin J.H. CSF as a surrogate for assessing CNS exposure: An industrial perspective. Current Drug Metabolism 2008, 9:46-59.
65. Marks J.D., Hoogenboom H.R., Bonnert T.P., McCafferty J., Griffiths A.D., Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. Journal of Molecular Biology 1991, 222:581-597.
66. McCafferty J., Griffiths A.D., Winter G., Chiswell D.J. Phage antibodies: Filamentous phage displaying antibody variable domains. Nature 1990, 348:552-554.
67. Moos T., Morgan E.H. Restricted transport of anti-transferrin receptor antibody (OX26) through the blood-brain barrier in the rat. Journal of Neurochemistry 2001, 79:119-129.
68. Muruganandam A., Tanha J., Narang S., Stanimirovic D. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB Journal 2002, 16:240-242.
69. Neuwelt E.A., Bauer B., Fahlke C., Fricker G., Iadecola C., Janigro D., et al. Engaging neuroscience to advance translational research in brain barrier biology. Nature Reviews. Neuroscience 2011, 12:169-182.
70. Niewoehner J., Bohrmann B., Collin L., Urich E., Sade H., Maier P., et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 2014, 81:49-60.
71. Nuttall S.D. Overview and discovery of IgNARs and generation of VNARs. Methods in Molecular Biology (Clifton, N.J.) 2012, 911:27-36.
72. Ohshima-Hosoyama S., Simmons H.A., Goecks N., Joers V., Swanson C.R., Bondarenko V., et al. A monoclonal antibody-GDNF fusion protein is not neuroprotective and is associated with proliferative pancreatic lesions in Parkinsonian monkeys. PLoS One 2012, 7:e39036.
73. Olafsen T. Fc engineering: Serum half-life modulation through FcRn binding. Methods in Molecular Biology 2012, 907:537-556.
74. Pardridge W.M. Drug and gene delivery to the brain: The vascular route. Neuron 2002, 36:555-558.
75. Pardridge W.M. Drug targeting to the brain. Pharmaceutical Research 2007, 24:1733-1744.
76. Pardridge W.M. Blood-brain barrier delivery. Drug Discovery Today 2007, 12:54-61.
77. Pardridge W.M., Boado R.J. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods in Enzymology 2012, 503:269-292.
78. Pardridge W., Buciak L., Friden P.M. Selective transport of an anti-transferrin through the blood-brain barrier in Vivo1 receptor antibody. Journal of Pharmacology and Experimental Therapeutics 1991, 259:66-70.
79. Pardridge W.M., Eisenberg J., Yang J. Human blood-brain barrier insulin receptor. Journal of Neurochemistry 1985, 44:1771-1778.
80. Pardridge W.M., Eisenberg J., Yang J. Human blood-brain barrier transferrin receptor. Metabolism 1987, 36:892-895.
81. Pardridge W.M., Kang Y.S., Buciak J.L., Yang J. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharmaceutical Research 1995, 12:807-816.
82. Pepinsky R., Shao Z., Ji B., Wang Q. Exposure levels of anti-LINGO-1 Li81 antibody in the central nervous system and dose-efficacy relationships in rat spinal cord remyelination models after systemic administration. Journal of Pharmacology and Experimental Therapeutics 2011, 339:519-529.
83. Persson M.A. Combinatorial libraries. International Reviews of Immunology 1993, 10:153-163.
84. Petit-Pedrol M., Armangue T., Peng X., Bataller L., Cellucci T., Davis R., et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: A case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurology 2014, 13:14-16.
85. Proetzel G., Roopenian D.C. Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies. Methods 2014, 65:148-153.
86. Régina A., Demeule M., Ché C., Lavallée I., Poirier J., Gabathuler R., et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector angiopep-2. British Journal of Pharmacology 2008, 155:185-197.
87. Ridgway J.B., Presta L.G., Carter P. "Knobs-into-holes" engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Engineering 1996, 9:617-621.
88. Sade H., Baumgartner C., Hugenmatter A., Moessner E., Freskgård P.-O., Niewoehner J. A human blood-brain barrier transcytosis assay reveals antibody transcytosis influenced by pH-dependent receptor binding. PLoS One 2014, 9:e96340.
89. Saerens D., Ghassabeh G.H., Muyldermans S. Single-domain antibodies as building blocks for novel therapeutics. Current Opinion in Pharmacology 2008, 8:600-608.
90. Sagare A.P., Deane R., Zlokovic B.V. Low-density lipoprotein receptor-related protein 1: A physiological Aβ homeostatic mechanism with multiple therapeutic opportunities. Pharmacology & Therapeutics 2012, 136:94-105.
91. Schlachetzki F., Zhu C., Pardridge W.M. Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. Journal of Neurochemistry 2002, 81:203-206.
92. Shatz W., Chung S., Li B., Marshall B., Tejada M., Phung W., et al. Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity. MAbs 2013, 5:872-881.
93. Shen D.D., Artru A.A., Adkison K.K. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Advanced Drug Delivery Reviews 2004, 56:1825-1857.
94. Smith M.W., Gumbleton M. Endocytosis at the blood-brain barrier: From basic understanding to drug delivery strategies. Journal of Drug Targeting 2006, 14:191-214.
95. Spencer B.J., Verma I.M. Targeted delivery of proteins across the blood-brain barrier. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:7594-7599.
96. Spiess C., Merchant M., Huang A., Zheng Z., Yang N.-Y., Peng J., et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nature Biotechnology 2013, 31:753-758.
97. Spreter Von Kreudenstein T., Lario P.I., Dixit S.B. Protein engineering and the use of molecular modeling and simulation: The case of heterodimeric Fc engineering. Methods 2014, 65:77-94.
98. St-Amour I., Paré I., Alata W., Coulombe K., Ringuette-Goulet C., Drouin-Ouellet J., et al. Brain bioavailability of human intravenous immunoglobulin and its transport through the murine blood-brain barrier. Journal of Cerebral Blood Flow & Metabolism 2013, 33:1983-1992.
99. Stanimirovic D.B., Friedman A. Pathophysiology of the neurovascular unit: Disease cause or consequence?. Journal of Cerebral Blood Flow & Metabolism 2012, 32:1207-1221.
100. Staus D.P., Wingler L.M., Strachan R.T., Rasmussen S.G.F., Pardon E., Ahn S., et al. Regulation of β2-adrenergic receptor function by conformationally selective single-domain intrabodies. Molecular Pharmacology 2014, 85:472-481.
101. Strazielle N., Ghersi-Egea J.F. Physiology of blood-brain interfaces in relation to brain disposition of small compounds and macromolecules. Molecular Pharmaceutics 2013, 10:1473-1491.
102. Strohl W.R. Optimization of Fc-mediated effector functions of monoclonal antibodies. Current Opinion in Biotechnology 2009, 20:685-691.
103. Stutz C.C., Zhang X., Shusta E.V. Combinatorial approaches for the identification of brain drug delivery targets. Current Pharmaceutical Design 2014, 20:1564-1576.
104. Sumbria R.K., Hui E.K.-W., Lu J.Z., Boado R.J., Pardridge W.M. Disaggregation of amyloid plaque in brain of Alzheimer's disease transgenic mice with daily subcutaneous administration of a tetravalent bispecific antibody that targets the transferrin receptor and the abeta amyloid peptide. Molecular Pharmaceutics 2013, 10:3507-3513.
105. Szentistványi I., Patlak C.S., Ellis R.A., Cserr H.F. Drainage of interstitial fluid from different regions of rat brain. The American Journal of Physiology 1984, 246:F835-F844.
106. Tanha J., Muruganandam A., Stanimirovic D. Phage display technology for identifying specific antigens on brain endothelial cells. Methods in Molecular Medicine 2003, 89:435-449.
107. Théry C. Exosomes: Secreted vesicles and intercellular communications. F1000 Biology Reports 2011, 3:15.
108. Thomas F.C., Taskar K., Rudraraju V., Goda S., Thorsheim H.R., Gaasch J.A., et al. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharmaceutical Research 2009, 26:2486-2494.
109. Vafa O., Gilliland G.L., Brezski R.J., Strake B., Wilkinson T., Lacy E.R., et al. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Methods 2014, 65:114-126.
110. Vincke C., Loris R., Saerens D., Martinez-Rodriguez S., Muyldermans S., Conrath K. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. The Journal of Biological Chemistry 2009, 284:3273-3284.
111. Von Kreudenstein T.S., Escobar-Carbrera E., Lario P.I., D'Angelo I., Brault K., Kelly J., et al. Improving biophysical properties of a bispecific antibody scaffold to aid developability: Quality by molecular design. MAbs 2013, 5:646-654.
112. Wang X.X., Cho Y.K., Shusta E.V. Mining a yeast library for brain endothelial cell-binding antibodies. Nature Methods 2007, 4:143-145.
113. Ward E.S., Güssow D., Griffiths A.D., Jones P.T., Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 1989, 341:544-546.
114. Wickramasinghe D. Tumor and T cell engagement by BiTE. Discovery Medicine 2013, 16:149-152.
115. Withoff S., Helfrich W., de Leij L.F., Molema G. Bi-specific antibody therapy for the treatment of cancer. Current Opinion in Molecular Therapeutics 2001, 3:53-62.
116. Wolak D.J., Thorne R.G. Diffusion of macromolecules in the brain: Implications for drug delivery. Molecular Pharmaceutics 2013, 10:1492-1504.
117. Yu Y.J., Zhang Y., Kenrick M., Hoyte K., Luk W., Lu Y., et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Science Translational Medicine 2011, 3. 84ra44.
118. Zlokovic B.V. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nature Reviews. Neuroscience 2011, 12:723-738.